Brief: Oragenics Announces Publication Of Positive Data For Its Nt-Cov2-1 Intranasal Covid-19 Vaccine Candidate In Scientific Reports
14/06/2022 12:36
June 14 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS ANNOUNCES PUBLICATION OF POSITIVE DATA FOR ITS
NT-COV2-1 INTRANASAL COVID-19 VACCINE CANDIDATE IN SCIENTIFIC
REPORTS
Source text for Eikon: ID:nBw9Dff29a
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing